With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short
Frank Vinluan , 2025-07-03 23:57:00 One of the more competitive targets in lung cancer is a certain mutation that has eluded many available targeted therapies. A drug developed by Dizal Pharmaceutical has received FDA approval for treating patients whose disease exhibits this genetic signature, giving the Shanghai-based company its first U.S. product along with the…